Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy

Journal of Urology

Volumn 182, Issue 1, 2009, Pages 125-132

  Donovan, Michael J ^a   Khan, Faisal M ^a   Fernandez, Gerardo ^a   Mesa Tejada, Ricardo ^a,b   Sapir, Marina ^a   Zubek, Valentina Bayer ^a   Powell, Douglas ^a   Fogarasi, Stephen ^a   Vengrenyuk, Yevgen ^a   Teverovskiy, Mikhail ^a   Segal, Mark R ^c   Karnes, R Jeffrey ^d   Gaffey, Thomas A ^d   Busch, Christer ^e   Haggman, Michael ^e   Hlavcak, Peter ^e   Freedland, Stephen J ^f   Vollmer, Robin T ^f   Albertsen, Peter ^g   Costa, Jose ^a,h   Cordon Cardo, Carlos ^a,b   more..

^a Aureon Laboratories Inc   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

androgen; biological markers; biopsy; prostate; prostatic neoplasms; receptors

Indexed keywords

ANDROGEN RECEPTOR; PARAFFIN;

ADULT; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349084186     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.135     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Holmberg L., Bill-Axelson A., Helgesen F., Salo J.O., Folmerz P., Haggman M., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781
3. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977
4. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 7 (2006) 355
5. Dall'Era M.A., Cooperberg M.R., Chan J.M., Davies B.J., Albertsen P.C., Klotz L.H., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112 (2008) 1650
6. Albertsen P.C., Hanley J.A., and Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
7. Telesca D., Etzioni R., and Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64 (2008) 10
8. Barry M.J., Kaufman D.S., and Wu C.L. Case 15-2008: a 55 year-old-man with an elevated prostate-specific antigen level and early-stage prostate cancer. N Engl J Med 358 (2008) 2161
9. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095
10. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco Jr. F.J., Dotan Z.A., Fearn P.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715
11. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
12. Cordon-Cardo C., Kotsianti A., Verbel D.A., Teverovsky M., Capodieci P., Hamann S., et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117 (2007) 1876
13. Donovan M.J., Hamann S., Clayton M., Khan F.M., Sapir M., Bayer-Zubek V., et al. A systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 26 (2008) 3923
14. van Diest P.J., Fleege J.C., and Baak J.P. Syntactic structure analysis in invasive breast cancer: analysis of reproducibility, biologic background, and prognostic value. Hum Pathol 23 (1992) 876
15. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
16. Bianco F.J. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urol Oncol Semin Orig Invest 26 (2008) 408
17. Smaletz O., Scher H.I., Small E.J., Verbel D., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972
18. Tu Y.K., Gunnell D., and Gilthorpe M.S. Simpson's paradox, Lord's paradox, and Suppression Effects are the same phenomenon-the reversal paradox. Emerg Themes Epidemiol 5 (2008) 2
19. Gonzalgo M.L., Bastian P.J., Mangold L.A., Trock B.J., Epstein J.I., Walsh P.C., et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 67 (2006) 115
20. Grober E.D., Tsihlias J., Jewett M.A., Sweet J.M., Evans A.J., Trachtenberg J., et al. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 11 (2004) 2157
21. Muntener M., Epstein J.I., Hernandez D.J., Gonzalgo M.L., Mangold L., Humpreys E., et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53 (2008) 767
22. Bubendorf L., Tapia C., Gasser T.C., Casella R., Grunder B., Moch H., et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29 (1998) 949
23. Mucci N.R., Rubin M.A., Strawderman M.S., Montie J.E., Smith D.C., and Pienta K.J. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 92 (2000) 1941
24. Pollack A., DeSilvio M., Khor L.Y., Li R., Al-Saleem T.I., Hammond M.E., et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22 (2004) 2133
25. Aaltomaa S., Karja V., Lipponen P., Isotalo T., Kankkunen J.P., Talja M., et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 26 (2006) 4873
26. Shimizu Y., Segawa T., Inoue T., Shiraishi T., Yoshida T., Toda Y., et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100 (2007) 685
27. Wang Y., Kreisberg J.I., and Ghosh P.M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 7 (2007) 591
28. McCall P., Gemmell L.K., Mukherjee R., Bartlett J., and Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 98 (2008) 1094
29. Khatami A., Pihl C.G., Norrby K., Hugosson J., and Damber J.E. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?. Acta Oncol 44 (2005) 362